Hemoglobin News and Research

RSS

A touch may go a long way for preterm babies

Therapeutic touch may have a protective effect on the autoregulation of cerebral blood flow in preterm neonates in response to pain, report researchers.

30 Jul 2012

Long-term linagliptin effective treatment for Type 2 diabetes

Linagliptin is an effective and well-tolerated therapy for the long-term management of Type 2 diabetes, say the authors of an open-label extension study published in the International Journal of Clinical Practice.

27 Jul 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

HemoGlobe device can identify women with anemia

Could a low-cost screening device connected to a cell phone save thousands of women and children from anemia-related deaths and disabilities? That's the goal of Johns Hopkins biomedical engineering undergraduates who've developed a noninvasive way to identify women with this dangerous blood disorder in developing nations. The device, HemoGlobe, is designed to convert the existing cell phones of health workers into a "prick-free" system for detecting and reporting anemia at the community level.

25 Jul 2012

New tool uses fluorescence to distinguish cancerous tissue from normal one in low-grade tumors

A new probe developed collaboratively at Norris Cotton Cancer Center and Dartmouth College's Thayer School of Engineering uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue from normal tissue. The probe tool, now already in use at the Cancer Center for brain surgery, may one day be used for surgeries for a variety of cancers.

25 Jul 2012

Linagliptin safe and effective for long-term management of type 2 diabetes

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication.

23 Jul 2012

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising.

23 Jul 2012

Periodontal examination can determine risk of diabetes

A recent study published in the Journal of Dental Research at Columbia University College of Dental Medicine (CDM) and backed by The Jeffrey Epstein VI Foundation amongst others; found that a pre-diabetes determination can be made by simply going to the dentist.

23 Jul 2012

Unexplained fatigue in women: start iron supplements

Iron deficiency may be underdiagnosed in women of child-bearing age who report considerable fatigue, say researchers whose randomized controlled trial results show a significant reduction in fatigue after women took iron supplements.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Iron deficiency in women ‘may be under-recognized’

Iron deficiency may be an under-recognized cause of fatigue in women, say investigators who report that iron supplementation reduced symptoms of fatigue in women who were not anemic but had low ferritin levels.

19 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Alogliptin adds benefits to diabetes monotherapy

Alogliptin is an effective add-on to glimepiride therapy for improving glycemic control in Japanese patients with Type 2 diabetes, show study findings.

18 Jul 2012

Marrow aspiration predicts smoldering multiple myeloma progression

Smoldering multiple myeloma patients with bone marrow plasma cell involvement should be treated immediately, say Italian researchers who found these patients are at greatest risk for symptomatic disease.

18 Jul 2012

Two cellular proteins team up to provide steady supply of RBCs

Two cellular proteins team up to provide a steady supply of red blood cells (RBCs), according to a study by Lizhao Wu, PhD, of the University of Medicine and Dentistry of New Jersey-New Jersey Medical School, and colleagues.

14 Jul 2012

Researchers evaluate new social media tool to treat type I and II diabetes

Researchers at the UC San Diego School of Medicine are evaluating a new social media tool called Wellaho to treat patients with type I and II diabetes. The clinical trial will study whether the use of social networking can improve patient-physician interactions and the patient's overall health and wellbeing.

13 Jul 2012

Thrombopoietin mimetic offers aplastic anemia hope

Eltrombopag significantly improves blood counts in some patients with refractory severe aplastic anemia, suggests research published in The New England Journal of Medicine.

11 Jul 2012

Anemia prevention in pregnancy works just as well with fewer iron supplements

Taking iron supplements one to three times a week instead of every day is just as effective at preventing anaemia in pregnant women, according to the findings of a new Cochrane systematic review. The authors of the review also showed that women experienced fewer side effects when taking iron supplements intermittently rather than daily.

11 Jul 2012

Two-drug combo increases diabetes patients’ goal achievement

Post-hoc analysis of randomized trial results shows that treating individuals with Type 2 diabetes with a combination of phentermine and topiramate increases their achievement of goals recommended for the management of their condition.

10 Jul 2012

Abbott announces CE Marking for ARCHITECT HbA1c assay

More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

10 Jul 2012